Literature DB >> 32317596

Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study.

Virginie Lemiale1, Stéphanie Pons2, Adrien Mirouse1, Jean-Jacques Tudesq1, Yannick Hourmant1, Djamel Mokart3, Frédéric Pène4, Achille Kouatchet5, Julien Mayaux6, Martine Nyunga7, Fabrice Bruneel8, Anne-Pascale Meert9, Edith Borcoman1, Magali Bisbal3, Matthieu Legrand1, Dominique Benoit10, Elie Azoulay1, Michaël Darmon1, Lara Zafrani1,2.   

Abstract

OBJECTIVES: Cancer affects up to 20% of critically ill patients, and sepsis is one of the leading reasons for ICU admission in this setting. Early signals suggested that survival might be increasing in this population. However, confirmation studies have been lacking. The goal of this study was to assess trends in survival rates over time in cancer patients admitted to the ICU for sepsis or septic shock over the last 2 decades. DATA SOURCE: Seven European ICUs. STUDY SELECTION: A hierarchical model taking into account the year of admission and the source dataset as random variables was used to identify risk factors for day 30 mortality. DATA EXTRACTION: Data from cancer patients admitted to ICUs for sepsis or septic shock were extracted from the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique database (1994-2015). DATA SYNTHESIS: Overall, 2,062 patients (62% men, median [interquartile range] age 59 yr [48-67 yr]) were included in the study. Underlying malignancies were solid tumors (n = 362; 17.6%) or hematologic malignancies (n = 1,700; 82.4%), including acute leukemia (n = 591; 28.7%), non-Hodgkin lymphoma (n = 461; 22.3%), and myeloma (n = 244; 11.8%). Two-hundred fifty patients (12%) underwent allogeneic hematopoietic stem cell transplantation and 640 (31.0%) were neutropenic at ICU admission. Day 30 mortality was 39.9% (823 deaths). The year of ICU admission was associated with significant decrease in day 30 mortality over time (odds ratio, 0.96; 95% CI, 0.93-0.98; p = 0.001). Mechanical ventilation (odds ratio, 3.25; 95% CI, 2.52-4.19; p < 0.01) and vasopressors use (odds ratio, 1.42; 95% CI, 1.10-1.83; p < 0.01) were independently associated with day 30 mortality, whereas underlying malignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia were not.
CONCLUSIONS: Survival in critically ill oncology and hematology patients with sepsis improved significantly over time. As outcomes improve, clinicians should consider updating admission policies and goals of care in this population.

Entities:  

Mesh:

Year:  2020        PMID: 32317596     DOI: 10.1097/CCM.0000000000004322

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

1.  Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.

Authors:  Mariana Chumbita; Pedro Puerta-Alcalde; Carlota Gudiol; Nicole Garcia-Pouton; Júlia Laporte-Amargós; Andrea Ladino; Adaia Albasanz-Puig; Cristina Helguera; Alba Bergas; Ignacio Grafia; Enric Sastre; María Suárez-Lledó; Xavier Durà; Carlota Jordán; Francesc Marco; Maria Condom; Pedro Castro; Jose A Martínez; Josep Mensa; Alex Soriano; Jordi Carratalà; Carolina Garcia-Vidal
Journal:  Antimicrob Agents Chemother       Date:  2021-11-29       Impact factor: 5.938

2.  Incidence of sepsis and associated mortality within the first year after cancer diagnosis in middle aged adults: A US population based study.

Authors:  Andry Van de Louw; Austin Cohrs; Douglas Leslie
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

Review 3.  Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.

Authors:  Carlota Gudiol; Adaia Albasanz-Puig; Guillermo Cuervo; Jordi Carratalà
Journal:  Front Med (Lausanne)       Date:  2021-03-31

4.  Predicting 30-days mortality for MIMIC-III patients with sepsis-3: a machine learning approach using XGboost.

Authors:  Nianzong Hou; Mingzhe Li; Lu He; Bing Xie; Lin Wang; Rumin Zhang; Yong Yu; Xiaodong Sun; Zhengsheng Pan; Kai Wang
Journal:  J Transl Med       Date:  2020-12-07       Impact factor: 5.531

5.  Differences in ICU Outcomes According to the Type of Anticancer Drug in Lung Cancer Patients.

Authors:  Yoonki Hong; Ji Young Hong; Jinkyeong Park
Journal:  Front Med (Lausanne)       Date:  2022-02-14

6.  Prognostic Impact of Neutropenia in Cancer Patients with Septic Shock: A 2009-2017 Nationwide Cohort Study.

Authors:  Sang-Min Kim; Youn-Jung Kim; Ye-Jee Kim; Won-Young Kim
Journal:  Cancers (Basel)       Date:  2022-07-24       Impact factor: 6.575

7.  Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.

Authors:  Pierrick Le Borgne; Léa Feuillassier; Maleka Schenck; Jean-Etienne Herbrecht; Ralf Janssen-Langenstein; Celestine Simand; Justine Gantzer; Simon Nannini; Luc-Matthieu Fornecker; Karine Alamé; François Lefebvre; Vincent Castelain; Francis Schneider; Raphaël Clere-Jehl
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

8.  All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis.

Authors:  Lama Nazer; Maria A Lopez-Olivo; John A Cuenca; Wedad Awad; Anne Rain Brown; Aseel Abusara; Michael Sirimaturos; Rachel S Hicklen; Joseph L Nates
Journal:  Support Care Cancer       Date:  2022-10-10       Impact factor: 3.359

9.  A 12-year study evaluating the outcomes and predictors of mortality in critically ill cancer patients admitted with septic shock.

Authors:  Wedad B Awad; Lama Nazer; Salam Elfarr; Maha Abdullah; Feras Hawari
Journal:  BMC Cancer       Date:  2021-06-16       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.